Cosentyx (secukinumab) is a prescription drug that’s used to treat conditions such as plaque psoriasis and psoriatic arthritis. Cosentyx is given as an injection under the skin or as an IV infusion.

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients ...

Novartis and Eli Lilly have been jockeying for new indications and commercial success for their IL-17 inhibitors Cosentyx and Taltz, respectively. Lilly appeared to get the label-expansion edge with ...

solution in a single-use Sensoready pen solution in a single-use UnoReady pen solution in a single-use prefilled syringe Cosentyx also comes as a solution in a single-use vial that’s given as an ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete more ...

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion and recommended granting ...

Please provide your email address to receive an email when new articles are posted on . Based on the recommendation, the European Commission will make a final decision within 2 months. If approved, ...

Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescribed Cosentyx (secukinumab) the ...